ResearcherInstituto Maimónides de Investigación Biomédica de CórdobaActive in the last 2 years
Pablo Cano-Ramírez
Matched on ORCID iD 0009-0006-0746-4037; OpenAlex author ID A5092518123. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper
Papers 3
- NR3C1, LAX1, and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metastatic Pancreatic Cancer. Co-author DOI 10.1002/mco2.70682↗
- Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer. First author DOI 10.1186/s13148-023-01535-4↗
- Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. First author DOI 10.1186/s40364-023-00528-y↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Maria Victoria García‐Ortiz · 3 shared papers, 2023–2026 · strength 0.73
- Paper NR3C1, LAX1, and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metas… DOI 10.1002/mco2.70682↗
- Paper Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. DOI 10.1186/s40364-023-00528-y↗
- Paper Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer. DOI 10.1186/s13148-023-01535-4↗
- Marta Toledano‐Fonseca · 3 shared papers, 2023–2026 · strength 0.73
- Paper NR3C1, LAX1, and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metas… DOI 10.1002/mco2.70682↗
- Paper Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. DOI 10.1186/s40364-023-00528-y↗
- Paper Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer. DOI 10.1186/s13148-023-01535-4↗
- Antonio Rodríguez‐Ariza · 3 shared papers, 2023–2026 · strength 0.73
- Paper NR3C1, LAX1, and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metas… DOI 10.1002/mco2.70682↗
- Paper Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. DOI 10.1186/s40364-023-00528-y↗
- Paper Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer. DOI 10.1186/s13148-023-01535-4↗
- Enrique Aranda Aguilar · 3 shared papers, 2023–2026 · strength 0.73
- Paper NR3C1, LAX1, and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metas… DOI 10.1002/mco2.70682↗
- Paper Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. DOI 10.1186/s40364-023-00528-y↗
- Paper Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer. DOI 10.1186/s13148-023-01535-4↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.